Expertise in
4
conditions

Dr. Michael J. Mccormack

Internal Medicine
Drs Newman Wooster Kass Bradford McCormack & Hurwitz P A
11110 Medical Campus Rd Ste 130, 
Hagerstown, MD 
Clinical Trials:Currently Recruiting for 2 Trials
44 Years of Experience
Expertise in
4
conditions
Drs Newman Wooster Kass Bradford McCormack & Hurwitz P A
11110 Medical Campus Rd Ste 130, 
Hagerstown, MD 

Overview

Michael Mccormack is a primary care provider, practicing in Internal Medicine in Hagerstown, Maryland. He has been practicing medicine for over 44 years.

Dr. Mccormack is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Mantle Cell Lymphoma (MCL).

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 12 clinical trials.

Graduate Year

1982

Specialties

Internal Medicine

Licenses

Internal Medicine in MD

Hospital Affiliations

Meritus Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Drs Newman Wooster Kass Bradford McCormack & Hurwitz P A
11110 Medical Campus Rd Ste 130, Hagerstown, MD 21742

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drug: Peposertib
Study Phase: Phase 1/Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials

1 Total Publications

Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.
Journal: Clinical genitourinary cancer
Published: February 09, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Thomas B. Nutman
Internal Medicine
Expertise in
19
conditions
Dr. Thomas B. Nutman
Internal Medicine

Office

4 Center Dr Bldg 4 Rm B1-03, 
Bethesda, MD 
 (56.5 miles away)
301-496-5398
Languages Spoken:
English
See accepted insurances

Thomas Nutman is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Nutman is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Secernentea Infections, Helminthiasis, Spirurida Infections, and Childhood Volvulus.

Expertise in
32
conditions
Dr. Ron Waksman
Internal Medicine
Expertise in
32
conditions
Dr. Ron Waksman
Internal Medicine
Before you request

110 Irving Street Northwest Suite 4B-1

110 Irving St NW Ste 4B-1, 
Washington, DC 
 (61.3 miles away)
202-877-7464
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ron Waksman is a primary care provider, practicing in Internal Medicine in Washington, Washington, D.c.. Dr. Waksman is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Coronary Heart Disease, Heart Attack, Acute Coronary Syndrome, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Waksman is currently accepting new patients.

Expertise in
19
conditions
Dr. Iago Pinal-Fernandez
Internal Medicine
Expertise in
19
conditions
Dr. Iago Pinal-Fernandez
Internal Medicine

Nih Niams Building 50

Bethesda, MD 
 (56.5 miles away)
202-361-2183
Languages Spoken:
English

Iago Pinal-Fernandez is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Pinal-Fernandez is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Myositis, Dermatomyositis, Polymyositis, Antisynthetase Syndrome, and Lung Transplant.

Frequently Asked Questions about Dr. Michael J. Mccormack

How do I make an appointment with Dr. Michael J. Mccormack?

You can book an appointment with Dr. Michael J. Mccormack by calling their office at 301-773-8600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael J. Mccormack a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael J. Mccormack is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael J. Mccormack specialize in?

While Dr. Michael J. Mccormack is a Internal Medicine, they have specific expertise in Breast Cancer, Familial Colorectal Cancer, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Michael J. Mccormack participate in research or clinical trials?

Yes. Dr. Michael J. Mccormack has published 1 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Michael J. Mccormack's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael J. Mccormack accept my insurance?

Dr. Michael J. Mccormack accepts most major insurance plans, including Humana and Medicare. We recommend calling the office directly at 301-773-8600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccormack's expertise for a condition
ConditionClose
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile